| Literature DB >> 35886020 |
Abstract
Identifying genes significantly related to diseases is a focus in the study of disease mechanisms. In this paper, from the perspective of integrated analysis and dynamic control, a method for identifying genes significantly related to diseases based on logic networks constructed by the LAPP method, referred to as NCCM, is proposed and applied to the study of the mechanism of acute myocardial infarction (AMI). It is found that 82.35% of 17 differential control capability genes (DCCGs) identified by NCCM are significantly correlated with AMI/MI in the literature and DISEASES database. The enrichment analysis of DCCGs shows that AMI is closely related to the positive regulation of vascular-associated smooth muscle cell proliferation and regulation of cytokine production involved in the immune response, in which HBEGF, THBS1, NR4A3, NLRP3, EDN1, and MMP9 play a crucial role. In addition, although the expression levels of CNOT6L and ACYP1 are not significantly different between the control group and the AMI group, NCCM shows that they are significantly associated with AMI. Although this result still needs further verification, it shows that the method can not only identify genes with large differences in expression but also identify genes that are associated with diseases but with small changes in expression.Entities:
Keywords: acute myocardial infarction (AMI); control capability; differential control capability genes (DCCGs)
Mesh:
Year: 2022 PMID: 35886020 PMCID: PMC9322919 DOI: 10.3390/genes13071238
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.141
Figure 1Flowchart for study methods. DCCGs differential control capability genes. DDM method for identifying differential nodes based on the degree.
Figure 2(a) Network assessment. Networks in the control and AMI groups are separable according to the average control capability of DEGs; (b) logic networks are presented under a threshold of 0.6. The logic networks of DEGs in the AMI group are more complex, compared to that in the control group. Genes represented by node numbers (Table S1).
Figure 3(a) Gene expression; (b) gene control capability; (c) proportion of genes with a control capability above that have been confirmed to be directly related to AMI/MI.
Category of DCCGs.
| Genes | Gene Names | Control | Gene | Functions in AMI/MI | AMI | MI |
|---|---|---|---|---|---|---|
| CAhighGeExphigh | ||||||
|
| Heparin-binding EGF-like growth factor | 11.5 | 0.215 | Upregulated | 2.1 | 3.4 |
|
| thrombospondin 1 | 8.714 | 0.395 | The development of heart failure after acute STEMI [ | 3.1 | 4.4 |
|
| nuclear receptor subfamily 4 group A member 3 | 6.684 | 0.422 | Inhibiting post-AMI inflammation responses via JAK2-STAT3/NF-kappa B signaling may well be a therapeutic target for cardiac remodeling after AMI [ | 1.2 | 2 |
|
| BCL6 transcription repressor | 4.808 | 0.239 | —— | 1.2 | 1.9 |
|
| NLR family pyrin domain-containing 3 | 3.216 | 0.411 | 3.7 | 4.7 | |
|
| intelectin 1 | 2.735 | 0.694 | The suppression of inflammation in the 6-month post-AMI period might have mediated the significant upregulation of omentin-1, implicating a novel target of treatment [ | 2.4 | 3.1 |
|
| pyruvate dehydrogenase kinase 4 | 2.375 | 0.348 | Following myocardial infarction, inducible deletion of | 1.9 | 3.4 |
| CAhighGeExplow | ||||||
|
| acylphosphatase 1 | 4.778 | −0.071 | —— | ||
|
| CCR4-NOT transcription complex subunit 6 like | 3.905 | 0.095 | —— | ||
| CAlowGeExphigh | ||||||
|
| vanin 3, pseudogene | 1.833 | 0.332 | Diagnostic biomarkers for STEMI [ | —— | 1.3 |
|
| C-X-C motif chemokine ligand 3 | 1.781 | 0.412 | Associated with reparative phases (post MI) [ | 1.1 | 2.6 |
|
| C-type lectin domain family 4 member D | 1.691 | 0.545 | Playing an important role in the occurrence and progression AMI [ | ||
|
| Leucine-rich α-2-glycoprotein 1 | 1.630 | 0.344 | 1.3 | 2.2 | |
|
| interleukin 1 receptor-associated kinase 3 | 1.607 | 0.456 | Silencing of | 2.2 | 2.8 |
|
| matrix metallopeptidase 9 | 1.575 | 0.377 | Inhibiting the chemokine signaling pathway and leukocyte transendothelial migration play a protective effect on AMI [ | 5 | 5.9 |
|
| endothelin 1 | 1.474 | 0.296 | 5.1 | 6.0 | |
|
| unnamed | 1.389 | 0.417 | —— |
DCCGs differential control capability genes; CA control capability; GeExp gene expression; here, the control capability fold-change means AMI/Control. Gene expression fold-change means (AMI-Control)/Control. High expression changes (fold-change > 0.2) with high control capability changes (fold-change > 2), defined as CAhighGeExphigh genes. —— means there is no direct literature to support it. The disease–gene associations Z-score were derived from automatic text mining of the biomedical literature (https://diseases.jensenlab.org/, accessed on 20 December 2021). The higher the Z-score, the better the correlation with it and the higher the trust.
Top seven gene enrichment outputs of DCCGs.
| Term | Description | LogP | Genes |
|---|---|---|---|
| GO:0048661 | positive regulation of smooth muscle cell proliferation | −8.93 | |
| GO:0002718 | regulation of cytokine production involved in immune response | −6.74 | |
| WP2865 | IL1 and megakaryocytes in obesity | −6.56 | |
| GO:0009617 | response to bacterium | −5.91 | |
| GO:1904707 | positive regulation of vascular associated smooth muscle cell proliferation | −5.74 | |
| hsa04668 | TNF signaling pathway | −4.57 | |
| M5885 | NABA MATRISOME ASSOCIATED | −4.49 |
Figure 4Enrichment of DCCGs. (a) Network of enriched terms: colored by cluster ID, where nodes that share the same cluster ID are typically close to each other. (b) Enrichment map of genes, where red indicates functional enrichment of genes and blue represents without enrichment. (c) The top-level GO biological processes of DCCGs.
Figure 5The Kyoto Encyclopedia of Genes and Genomes pathway of differentially control capability genes. Red diamonds represent the DCCGs in AMI. (a) Bladder cancer. (b) Transcriptional misregulation in cancer. (c) TNF signaling pathway involved in MMP9, EDN1, and CXCL3. (d) Relaxin signaling pathway. (e) Fluid shear stress and atherosclerosis.
Figure 6Network assessment. Networks in the control and AMI groups are separable according to the average degree of DEGs.
Category of DDGs.
| Genes | Gene Names | AMI | MI |
|---|---|---|---|
|
| interleukin 1 receptor-associated kinase 3 | 2.2 | 2.8 |
|
| intelectin 1 | 2.4 | 3.1 |
|
| BCL6 transcription repressor | 1.2 | 1.9 |
|
| C-X-C motif chemokine ligand 3 | 1.1 | 2.6 |
|
| nuclear receptor subfamily 4 group A member 3 | 1.2 | 2 |
|
| C-type lectin domain family 4 member D | —— | —— |
|
| cell division cycle 25B | —— | —— |
|
| unnamed | —— | —— |
|
| matrix metallopeptidase 9 | 5 | 5.9 |
|
| glutamate-ammonia ligase | —— | 1.9 |
|
| fat storage-inducing transmembrane protein 2 | —— | —— |
|
| inositol 1,4,5-trisphosphate receptor-interacting protein | —— | —— |
|
| meteorin-like, glial cell differentiation regulator | —— | —— |
|
| GABA type A receptor-associated protein-like 1 | 1.5 | 2.9 |
|
| ring finger protein 144B | —— | —— |
|
| NLR family pyrin domain-containing 3 | 3.7 | 3.7 |
|
| annexin A3 | 2.1 | 2.9 |
—— Indicates not scored in DISEASES. Bold indicates the same genes as those screened in NCCM.
Figure 7(a) HBEGF, THBS1, NR4A3, NLRP3, EDN1, MMP9 interaction network at the 0.4 threshold. (b) HBEGF, THBS1, NR4A3, NLRP3, EDN1, MMP9, ACYP1, CNOT6L interaction network at the 0.15 threshold.